{"title":"Research progress of monoclonal antibodies in treatment of multiple myeloma","authors":"Y. Liao, Mengyao Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.01.009","DOIUrl":null,"url":null,"abstract":"The treatment of multiple myeloma (MM) has developed rapidly in the past decade, due to the notable effect of protease inhibitors (PI) and immunomodulatory drugs (IMID). However, MM remains incurable in the vast majority of cases. Recently, a large number of studies have found that monoclonal antibodies, such as a targeted approach can significantly increase remission rate or survival for patients with MM, including relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). This review focuses on the recent developments in monoclonal antibody-based therapy for MM in terms of targets, efficacy and safety. \n \n \nKey words: \nMultiple myeloma; Antibodies, monoclonal; Antigens; Molecular targeted therapy; Treatment outcome; Clinical protocols; Drug-related side effects and adverse reactions","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"53-60"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The treatment of multiple myeloma (MM) has developed rapidly in the past decade, due to the notable effect of protease inhibitors (PI) and immunomodulatory drugs (IMID). However, MM remains incurable in the vast majority of cases. Recently, a large number of studies have found that monoclonal antibodies, such as a targeted approach can significantly increase remission rate or survival for patients with MM, including relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). This review focuses on the recent developments in monoclonal antibody-based therapy for MM in terms of targets, efficacy and safety.
Key words:
Multiple myeloma; Antibodies, monoclonal; Antigens; Molecular targeted therapy; Treatment outcome; Clinical protocols; Drug-related side effects and adverse reactions
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
